theophylline has been researched along with tacrine in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 17 (58.62) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, J; Chen, X; Huang, L; Li, X; Sun, Y | 1 |
| Huang, L; Li, X; Meng, F; Miao, H; Sun, Y | 1 |
| Bajda, M; Brus, B; Gobec, S; Guzior, N; Malawska, B; Rakoczy, J | 1 |
| Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K | 1 |
| Aitken, L; Benek, O; Dohnal, V; Dolezal, R; Guest, P; Gunn-Moore, F; Hroch, L; Janockova, J; Kuca, K; Musil, K; Musilek, K; Smith, TK; Soukup, O | 1 |
| Bienkowski, P; Bucki, A; Gobec, S; Godyń, J; Głuch-Lutwin, M; Kazek, G; Knez, D; Kołaczkowski, M; Malawska, B; Marcinkowska, M; Mierzejewski, P; Sienkiewicz-Jarosz, H; Siwek, A; Wichur, T; Więckowska, A; Więckowski, K; Zaręba, P | 1 |
| Bajda, M; Gobec, S; Godyń, J; Janockova, J; Jończyk, J; Knez, D; Korabecny, J; Malawska, B; Mika, K; Panek, D; Soukup, O; Wichur, T; Więckowska, A | 1 |
| Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Andrisano, V; Apperley, KYP; Bartolini, M; Baschieri, A; Basso, M; Chen, HH; De Simone, A; Guardigni, M; Keillor, JW; Kobrlova, T; Milelli, A; Montanari, S; Soukup, O; Valgimigli, L | 1 |
| Azzouz, R; Gembus, V; Levacher, V; Papamicaël, C; Peauger, L; Sopková-de Oliveira Santos, J; Ţînţaş, ML | 1 |
| Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S | 1 |
| Boulouard, M; Claeysen, S; Corvaisier, S; Dallemagne, P; Davis, A; Freret, T; Hatat, B; Lalut, J; Lecoutey, C; Rochais, C; Since, M; Sopková-de Oliveira Santos, J; Toublet, FX | 1 |
| de Belleroche, J; Gardiner, IM | 1 |
| Curley, WH; Dretchen, KL; Standaert, FG | 1 |
| Adams, DA; Davies, DS; Edwards, RJ; Madden, S; Park, BK; Spaldin, V | 1 |
| Bezek, S; Kukan, M; Pool, WF; Woolf, TF | 1 |
| Choi, H; Lee, J; Park, TG | 1 |
| Jalali, A; Kawa, K; Larsen, C; Trevitt, J | 1 |
29 other study(ies) available for theophylline and tacrine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electrophorus; Humans; Isoflavones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Swine; Tacrine | 2013 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Indans; Inhibitory Concentration 50; Ligands; Peptide Fragments; Permeability; Protein Aggregates | 2014 |
Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Delivery Systems; Drug Design; Drug Evaluation, Preclinical; Horses; Humans; Indoles; Protein Structure, Secondary | 2015 |
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Humans; Indans; Indoles; Male; Memory; Mice; Models, Molecular; Neuroprotective Agents; Phthalimides; Piperidines; Protein Aggregates; Scopolamine; Structure-Activity Relationship | 2015 |
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Urea | 2016 |
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Catalytic Domain; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Ligands; Male; Models, Molecular; Molecular Targeted Therapy; Protein Conformation; Rats; Rats, Wistar; Receptors, Serotonin | 2016 |
Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.
Topics: Amines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Binding Sites; Blood-Brain Barrier; Cholinesterases; Drug Delivery Systems; Drug Design; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregation, Pathological; Protein Binding; Saccharin | 2017 |
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cell Death; Cell Line; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Naphthalenes; Peptide Fragments; Piperidines; Structure-Activity Relationship; Sulfonamides | 2017 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; Glycogen Synthase Kinase 3 beta; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2017 |
Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine "bio-oxidizable" prodrugs: Synthesis, biological evaluation and structure-activity relationship.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dihydropyridines; Dose-Response Relationship, Drug; Electrophorus; Horses; Molecular Docking Simulation; Molecular Structure; Prodrugs; Pyridinium Compounds; Salts; Structure-Activity Relationship | 2018 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines | 2018 |
Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Humans; Locomotion; Male; Mice; Models, Molecular; Molecular Structure; Prodrugs; Receptors, Serotonin; Structure-Activity Relationship | 2021 |
Modulation of gamma-aminobutyric acid release in cerebral cortex by fluoride, phorbol ester, and phosphodiesterase inhibitors: differential sensitivity of acetylcholine release to fluoride and K+ channel blockers.
Topics: 1-Methyl-3-isobutylxanthine; Acetylcholine; Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Phorbol Esters; Phosphodiesterase Inhibitors; Potassium; Potassium Channels; Rats; Sodium Fluoride; Tacrine; Theophylline | 1990 |
Physostigmine inhibition of 3',5'-cyclic AMP phosphodiesterase from cat sciatic nerve.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cats; Etazolate; Hydrogen-Ion Concentration; In Vitro Techniques; Neuromuscular Junction; Physostigmine; Sciatic Nerve; Tacrine; Theophylline | 1984 |
Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe.
Topics: Amino Acid Sequence; Biotransformation; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Humans; Immunoblotting; In Vitro Techniques; Isoenzymes; Liver; Molecular Sequence Data; Nootropic Agents; Oxidoreductases; Phosphodiesterase Inhibitors; Spectrophotometry, Ultraviolet; Substrate Specificity; Tacrine; Theophylline | 1995 |
The effect of cytochromes P4501A induction and inhibition on the disposition of the cognition activator tacrine in rat hepatic preparations.
Topics: Animals; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Enoxacin; Enzyme Induction; Etimizol; Glucuronidase; Glutathione; Liver; Male; Methylcholanthrene; Rats; Rats, Wistar; Tacrine; Theophylline | 1996 |
Effect of formulation and processing variables on the characteristics of microspheres for water-soluble drugs prepared by w/o/o double emulsion solvent diffusion method.
Topics: Acetaminophen; Acrylic Resins; Corn Oil; Diffusion; Dose-Response Relationship, Drug; Drug Compounding; Emulsions; Methylene Chloride; Microspheres; Polymethacrylic Acids; Propranolol; Solvents; Surface-Active Agents; Tacrine; Temperature; Theophylline; Water | 2000 |
Differential effects of adenosine antagonists in two models of parkinsonian tremor.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Synergism; Jaw; Male; Parkinsonian Disorders; Pimozide; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Tacrine; Theophylline; Tremor; Triazoles | 2009 |